Clinical trials: Macular Pigment, active
Intermediate AMD
A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD
The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on therapeutic effect.
- Trial name
- retinaSEES-PoC (NCT06557369)
- Testing
- reSEES
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Oculox Technologies SA
Hypopigmentation
Characterization of Bacterial and Mycosis Skin Flora in Seborrheic Macular Hypopigmentation - Microbiome
Hypopigmented skin changes are commonly encountered by dermatologists. A new dermatological entity was identified as scattered, hypopigmented oval-shaped macules and patches distributed mostly in seborrheic area of the face and…
- Trial name
- Microbiome_SHM (NCT06908889)
- Testing
- Skin's lesion patients, Skin's lesion vulunteers
- Where
- 3 sites in France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Macular Pigmentation, Skin Pigment
Macular Pigment Measurements in Eye & Other Tissues
The purpose of this study is to understand the role of nutrition and its effects on the eye and other tissues. The investigators propose to study this by validating and correlating various non-invasive measurement methods of…
- Trial name
- NCT03022773
- Testing
- Carotenoid measurements
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- University of Utah
Cognitive Performance, Age-Related Macular Degeneration
Lutein, Zeaxathin, and Fish Oil Supplementation
The goal of this clinical trial is to learn the impact of lutein, zeaxanthin, and fish oil (LZF) supplementation in healthy adults.
- Conditions
- Cognitive Performance, Age-Related Macular Degeneration, Bone Loss
- Trial name
- NCT06489873
- Testing
- Active Comparator (Lutein, zeaxanthin, and fish oil supplement (LZF)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
AMD - Age-Related Macular Degeneration
Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular…
- Trial name
- NCT07418177
- Testing
- hiPSC-RPEs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Dry Age-Related Macular Degeneration, Geographic Atrophy
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
- Trial name
- NCT04339764
- Testing
- iPSC-derived RPE/PLGA transplantation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Geographic Atrophy, Stargardt Disease
Phase 1 Study of C.001 in Retinal Degeneration
This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.
- Conditions
- Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
- Trial name
- NCT07594236
- Testing
- Injection
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Cellio Therapeutics Inc
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
Vitiligo - Macular Depigmentation, Tacrolimus
COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
- Trial name
- NB-UVB (NCT06880042)
- Testing
- Tacrolimus, Calcipotriol
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Dr ayesha wahid
Macular Degeneration
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration
This project intends to perform autologous transplantation of induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE).
- Trial name
- NCT05445063
- Testing
- Autologous iPSC-derived RPE
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Beijing Tongren Hospital
Age Related Macular Degeneration
Retinal Pigment Epithelium Safety Study For Patients In B4711001
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety.
- Trial name
- NCT03102138
- Where
- 2 sites in United Kingdom
- Volunteers
- 10 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Epiretinal Membrane, Dry Age Related Macular Degeneration
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.
- Conditions
- Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease
- Trial name
- NCT07680244
- Testing
- PathFinder 1.0 on CIRRUS HD-OCT
- Where
- 6 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec-Dublin CoCe
Macular Degenerative Disease
A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy
The purpose of this study is to is to evaluate the occurrence of late onset (i.e., greater than 5 years after treatment) adverse events of special interest (AESI) in participants who have received sub-retinal transplant of human…
- Trial name
- NCT03167203
- Testing
- Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 36 people
- Sponsor
- Astellas Institute for Regenerative Medicine
Retinal Disease, Macular Degeneration
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
The goal of this clinical study is to evaluate the safety and efficacy of novel stem cell formulation in patients having Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD).
- Conditions
- Retinal Disease, Macular Degeneration, Age-Related Macular Degeneration, Geographic Atrophy
- Trial name
- NCT06394232
- Testing
- Eyecyte-RPE™
- Where
- 3 sites in India
- Volunteers
- 54 people
- Sponsor
- Eyestem Research Pvt. Ltd.
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a corresponding biobank of DNA samples from people with a…
- Conditions
- Inherited Ophthalmic Diseases, Hypopigmentation Disorder, Corneal Dystrophy, Blue-cone Monochromacy
- Trial name
- NCT06491615
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- National Eye Institute (NEI)
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
AMD - Age-Related Macular Degeneration
Comparison of the Sensibility of Swept Source Optical Coherence Tomography Devices in the Detection of Neovascularisation in Large Pigment Epithelium Detachments
The goal of this observational study is to compare swept source optical coherence tomography devices ability to detect macular neovascularisation when there is a large pigment epithelium detachment higher than 250 microns
- Trial name
- NCT07143526
- Testing
- Optical Coherence Tomography Angiography (OCT-A)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University of Trieste